Advertisement
Advertisement
U.S. markets close in 1 hour 4 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Aclaris Therapeutics, Inc. (ACRS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.25-0.49 (-3.11%)
As of 02:54PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close15.74
Open15.85
Bid15.16 x 1100
Ask15.19 x 900
Day's Range15.17 - 15.89
52 Week Range9.26 - 18.75
Volume181,148
Avg. Volume329,415
Market Cap1.017B
Beta (5Y Monthly)0.60
PE Ratio (TTM)N/A
EPS (TTM)-1.36
Earnings DateOct 31, 2022 - Nov 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACRS

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Aclaris Therapeutics, Inc.
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID stocks) have underperformed large-caps over the past 12 months, but still may be in a better position to generate market-beating returns going forward. For one thing, SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from the Russian invasion of Ukraine. As well, the prices of SMID stocks generally are lower than the prices of large-caps. SMID stocks can be risky -- and large-caps outperformed SMID stocks in 11 of the 19 years in our test period. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 12%-15% of the U.S. stock market's capitalization is comprised of SMID stocks. For our purposes, we use a threshold of $20 billion to define a SMID stock.
    Rating
    Fair Value
    Economic Moat
    7 days agoArgus Research
View more
Advertisement
Advertisement